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Main Text
Introductory paragraph
Prostate cancers remain indolent in the majority of patients but behave aggressively in a 
minority1,2. However, the molecular basis for this clinical heterogeneity remains 
incompletely understood3-5. Here, we characterize a novel lncRNA termed SChLAP1 
(Second Chromosome Locus Associated with Prostate-1, HGNC #48603) overexpressed in a 
subset of prostate cancers. SChLAP1 levels independently predicted for poor patient 
outcomes, including metastasis and prostate cancer specific mortality. In vitro and in vivo 
gain-of-function and loss-of-function experiments indicated that SChLAP1 is critical for 
cancer cell invasiveness and metastasis. Mechanistically, SChLAP1 antagonized the 
genome-wide localization and regulatory functions of the SWI/SNF chromatin-modifying 
complex. These results suggest that SChLAP1 contributes to the development of lethal 
cancer at least in part by antagonizing tumor-suppressive functions of the SWI/SNF 
complex.
Manuscript text
With over 200,000 diagnoses per year, 1 in 6 U.S. men are diagnosed with prostate cancer 
during their lifetime. Yet, only 20% of prostate cancer patients have a high-risk cancer that 
represents possibly lethal disease1,2,4. While mutational events in key genes characterizes a 
subset of lethal prostate cancers3,5,6, the molecular basis for aggressive disease remains 
poorly understood.
Long non-coding RNAs (lncRNAs) are RNA species >200bp in length that are frequently 
polyadenylated and associated with transcription by RNA polymerase II7. lncRNA-mediated 
biology has been implicated in a wide variety of cellular processes and in cancer, lncRNAs 
are emerging as a prominent layer of transcriptional regulation, often by collaborating with 
epigenetic complexes7-10.
Here, we hypothesized that prostate cancer aggressiveness was governed by uncharacterized 
lncRNAs and sought to discover lncRNAs associated with aggressive disease. We 
previously used RNA-Seq to describe 121 novel lncRNA loci (out of >1,800) that were 
aberrantly expressed in prostate cancer tissues11. Because only a fraction of prostate cancers 
present with aggressive clinical features2, we performed cancer outlier profile analysis11 
(COPA) to nominate intergenic lncRNAs selectively upregulated in a subset of cancers 
(Supplementary Table 1). We observed that only two, PCAT-109 and PCAT-114, which are 
both located in a “gene desert” on Chromosome 2q31.3 (Supplementary Fig. 1), showed 
striking outlier profiles and ranked among the best outliers in prostate cancer11 (Fig. 1a).
Of the two, PCAT-114 was expressed at higher levels in prostate cell lines, and in the 
PCAT-114 region we defined a 1.4 kb, polyadenylated gene composed of up to seven exons 
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and spanning nearly 200kb on Ch2q31.3 (Fig. 1b and Supplementary Fig. 2a). We named 
this gene Second Chromosome Locus Associated with Prostate-1 (SChLAP1) after its 
genomic location. Published prostate cancer ChIP-Seq data12 confirmed that the 
transcriptional start site (TSS) of SChLAP1 was marked by H3K4 trimethylation 
(H3K4me3) and its gene body harbored H3K36 trimethylation (H3K36me3) (Fig. 1b), an 
epigenetic signature consistent with lncRNAs13. We observed numerous SChLAP1 splicing 
isoforms of which three (termed isoforms #1, #2, and #3, respectively) constituted the vast 
majority (>90%) of transcripts in the cell (Supplementary Fig. 2b,c).
Using quantitative PCR (qPCR), we validated that SChLAP1 was highly expressed in ∼25% 
of prostate cancers (Fig. 1c). SChLAP1 prevalence was more frequent in metastatic 
compared to localized prostate cancers and was associated with ETS gene fusions in this 
cohort but not other molecular events (Supplementary Fig. 2d,e). A computational analysis 
of the SChLAP1 sequence suggested no coding potential, which was confirmed 
experimentally by in vitro translation assays of three SChLAP1 isoforms (Supplementary 
Fig. 3). Additionally, we found that SChLAP1 transcripts were located in the nucleus (Fig. 
1d). We confirmed the nuclear localization of SChLAP1 in human samples (Fig. 1e) using 
an in situ hybridization (ISH) assay in formalin-fixed paraffin-embedded (FFPE) prostate 
cancers (Supplementary Fig. 4a,b and Supplementary Note).
An analysis of SChLAP1 expression in localized tumors demonstrated a striking correlation 
with higher Gleason scores, a histopathological measure of aggressiveness (Supplementary 
Fig. 4c,d and Supplementary Table 2). Next, we performed a network analysis of prostate 
cancer microarray data in the Oncomine14 database using signatures of SChLAP1-correlated 
or -anti-correlated genes, given that SChLAP1 is not measured by expression microarrays 
(Supplementary Table 3a and Online Methods). We found a remarkable association with 
enriched concepts related to prostate cancer progression (Fig. 2a and Supplementary Table 
3b). For comparison, we next incorporated disease signatures using prostate RNA-seq data 
as well as additional known prostate cancer genes: EZH2, a metastasis gene15, PCA3, a 
lncRNA biomarker4, AMACR, a tissue biomarker4, and β-actin (ACTB) as a control 
(Supplementary Fig. 5, Supplementary Tables 3c-i, and Supplementary Note). A heat-map 
visualization of significant comparisons confirmed a strong association of SChLAP1-
correlated genes, but not PCA3- and AMACR-correlated genes, with high-grade and 
metastatic cancers (Fig. 2b). Kaplan-Meier analysis similarly showed significant 
associations between the SChLAP1 signature and biochemical recurrence16 and overall 
survival17 (Supplementary Fig. 6a,b).
To evaluate SChLAP1 levels with clinical outcomes directly, we next used SChLAP1 
expression to stratify 235 radical prostatectomy localized prostate cancer patients from the 
Mayo Clinic18 (Supplementary Fig. 6c and Online Methods). Samples were evaluated for 
three clinical endpoints: biochemical recurrence (BCR), clinical progression to systemic 
disease (CP), and prostate cancer-specific mortality (PCSM) (Supplementary Table 4). At 
the time of this analysis, patients had a median follow-up of 8.1 years.
SChLAP1 was a powerful single-gene predictor of aggressive prostate cancer (Fig. 2c-e). 
SChLAP1 expression was highly significant when distinguishing CP and PCSM (p = 
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0.00005 and p = 0.002, respectively) (Fig. 2d,e). For the BCR endpoint, high SChLAP1 
expression was associated with a rapid median time-to-progression (1.9 vs 5.5 years for 
SChLAP1 high and low patients, respectively) (Fig. 2c). We further confirmed that this 
association with rapid BCR using an independent cohort (Supplementary Fig. 6d). 
Multivariable and univariable regression analyses of the Mayo Clinic data demonstrated that 
SChLAP1 expression is an independent predictor of prostate cancer aggressiveness with 
highly significant hazard ratios for predicting BCR, CP, and PCSM (HR or 3.045, 3.563, 
and 4.339, respectively, p < 0.01) which were comparable to other clinical factors such as 
advanced clinical stage and the Gleason histopathological score (Supplementary Fig. 7 and 
Supplementary Note).
To explore the functional role for SChLAP1, we performed siRNA knockdowns to compare 
the impact of SChLAP1 depletion to that of EZH2, which is essential for cancer cell 
aggressiveness15. Remarkably, knockdown of SChLAP1 dramatically impaired cell invasion 
and proliferation in vitro at a level comparable to EZH2 (Fig. 3a and Supplementary Fig. 
8a,b). Overexpression of a siRNA-resistant SChLAP1 isoform rescued the in vitro invasive 
phenotype of 22Rv1 cells treated with siRNA-2 (Supplementary Fig. 8c,d). Next, 
overexpression of three SChLAP1 isoforms in RWPE benign immortalized prostate cells 
dramatically increased the ability of these cells to invade in vitro but did not impact cell 
proliferation (Fig. 3b and Supplementary Fig. 8e,f).
To test SChLAP1 in vivo, we performed intracardiac injection of 22Rv1 cells stably 
knocking down SChLAP1 (Supplementary Fig. 9a) and observed that SChLAP1 depletion 
impaired metastatic seeding and growth by luciferase signaling at both proximal (lungs) and 
distal sites (Fig. 3c,d). Indeed, 22Rv1 shSChLAP1 cells displayed both fewer gross 
metastatic sites overall as well as smaller metastatic tumors when they did form (Fig. 3d,e). 
Histopathological analysis of the metastatic 22Rv1 tumors, regardless of SChLAP1 
knockdown, showed uniformly high-grade epithelial cancer (Supplementary Fig. 9b). 
Interestingly, shSChLAP1 subcutaneous xenografts displayed slower tumor progression; 
however this was due to delayed tumor engraftment rather than decreased tumor growth 
kinetics with no change in Ki67 staining observed between shSChLAP1 and shNT cells 
(Supplementary Fig. 9c-i).
Next, using the chick chorioallantoic membrane (CAM) assay19, we found that 22Rv1 
shSChLAP1 #1 cells, which have depleted expression of both isoforms 1 and 2, 
demonstrated a greatly reduced ability to invade, intravasate and metastasize distant organs 
(Fig. 3f-h). Additionally, shSChLAP1 cells also showed decreased tumor growth (Fig. 3i). 
Importantly, overexpression of RWPE-SChLAP1 isoform #1 cells partially recapitulated 
these results, displaying a markedly increased ability to intravasate (Fig. 3j). RWPE-
SChLAP1 cells did not generate distant metastases or cause altered tumor growth in this 
model (data not shown). Together, the murine metastasis and CAM data strongly implicate 
SChLAP1 in tumor invasion and metastasis through cancer cell intravasation, extravasation, 
and subsequent tumor cell seeding.
To elucidate mechanisms of SChLAP1 function, we profiled 22Rv1 and LNCaP SChLAP1-
knockdown cells, which revealed 165 upregulated and 264 downregulated genes (q-value < 
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0.001) (Supplementary Fig. 10a and Supplementary Table 5a). After ranking genes 
according to differential expression20, we employed Gene Set Enrichment Analysis 
(GSEA)21 to search for enrichment across the Molecular Signatures Database (MSigDB)22. 
Among the highest ranked concepts we noticed genes positively or negatively correlated 
with the SWI/SNF complex23, which was independently confirmed using gene signatures 
generated from our RNA-Seq data (Supplementary Fig. 10b-e, and Supplementary Table 
5b,c). Importantly, SChLAP1-regulated genes were inversely correlated with these datasets, 
suggesting that SChLAP1 and SWI/SNF function in opposing manners.
The SWI/SNF complex regulates gene transcription as a multi-protein system that physically 
move nucleosomes at gene promoters24. Loss of SWI/SNF functionality promotes cancer 
progression and multiple SWI/SNF components are somatically inactivated in cancer24,25. 
SWI/SNF mutations do occur in prostate cancer albeit not commonly3, and down-regulation 
of SWI/SNF complex members characterizes subsets of prostate cancer23,26. Thus, 
antagonism of SWI/SNF activity by SChLAP1 is consistent with the oncogenic behavior of 
SChLAP1 and the tumor suppressive behavior of the SWI/SNF complex.
To directly test whether SChLAP1 antagonizes SWI/SNF-mediated regulation, we 
performed siRNA knockdown of SNF5 (also known as SMARCB1) (Supplementary Fig. 
10f), an essential subunit that facilitates SWI/SNF binding to histone proteins24,25,27, and 
confirmed predicted expression changes for several SChLAP1 or SNF5-regulated genes 
(Supplementary Fig. 10g,h). A comparison of genes regulated by knockdown of SNF5 to 
genes regulated by SChLAP1 demonstrated an antagonistic relationship where SChLAP1 
knockdown affected the same genes as SNF5 but in the opposing direction (Fig. 4a and 
Supplementary Tables 5d-h). We used GSEA to quantify and verify the significance of these 
findings (FDR < 0.05) (Supplementary Fig. 10i-k). Furthermore, a shared SNF5-SChLAP1 
signature of co-regulated genes was highly enriched for prostate cancer clinical signatures 
for disease aggressiveness (Supplementary Fig. 11 and Supplementary Table 5i).
Mechanistically, although SChLAP1 and SNF5 mRNA levels were comparable 
(Supplementary Fig. 12a), SChLAP1 knockdown or overexpression did not alter SNF5 
protein abundance (Supplementary Fig. 12b), suggesting that SChLAP1 regulates SWI/SNF 
activity post-translationally. To explore this possibility, we performed RNA 
immunoprecipitation assays (RIP) for SNF5. We found that endogenous SChLAP1, but not 
other cytoplasmic or nuclear lncRNAs7,28, robustly co-immunoprecipitated with SNF5 in 
both native (Fig. 4b) and UV-crosslinked conditions (Supplementary Fig. 12c) as well as 
with a second SNF5 antibody (Supplementary Fig. 12d). In contrast, SChLAP1 did not co-
immunoprecipitate with androgen receptor (Fig. 4b). Furthermore, both SChLAP1 isoform 
#1 and isoform #2 co-immunoprecipitated with SNF5 in RWPE overexpression models (Fig. 
4c and Supplementary Fig. 12e). SNRNP70 binding to the U1 RNA was used as a technical 
control in all cell lines (Supplementary Fig. 12f,g). Finally, pulldown of the SChLAP1 RNA 
in RWPE-SChLAP1 isoform #1 cells robustly recovered SNF5 protein, confirming this 
interaction (Fig. 4d and Supplementary Fig. 12h).
To address whether SChLAP1 modulated SWI/SNF genomic binding, we performed ChIP-
Seq of SNF5 in RWPE-LacZ and RWPE-SChLAP1 cells and called significantly enriched 
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peaks with respect to an IgG control (Supplementary Table 6a and Online Methods). 
Western blot validations confirmed SNF5 pull-down by ChIP (Supplementary Fig. 13a), 
After aggregating called peaks from all samples, we found 6,235 genome-wide binding sites 
for SNF5 (FDR < 0.05, Supplementary Table 6b), which were highly enriched for sites near 
gene promoters (Supplementary Fig. 13b), supporting previous studies of SWI/SNF 
binding29-31.
A comparison of SNF5 binding across these 6,235 genomic sites demonstrated a dramatic 
decrease in SNF5 genomic binding as a result of SChLAP1 overexpression (Fig. 4e,f and 
Supplementary Fig. 13c). Of the 1,299 SNF5 peaks occurring within 1kb of a gene 
promoter, 390 decreased ≥2-fold in relative SNF5 binding (Supplementary Fig. 13d and 
Supplementary Table 6c). To verify these findings independently, we performed ChIP for 
SNF5 in 22Rv1 sh-SChLAP1 cells, with the hypothesis that knockdown of SChLAP1 should 
increase SNF5 genomic binding compared to controls. We found that 9 of 12 target genes 
showed a substantial increase in SNF5 binding (Supplementary Fig. 14a), confirming our 
predictions.
Finally, we used expression profiling of RWPE-LacZ and RWPE-SChLAP1 cells to 
characterize the relationship between SNF5 binding and SChLAP1-mediated gene 
expression changes. After identifying a gene signature with highly significant expression 
changes (Supplementary Table 6d), we intersected this signature with the ChIP-Seq data. 
We observed that a significant subset of genes with ≥2-fold relative decrease in SNF5 
genomic binding were dysregulated when SChLAP1 was overexpressed (Supplementary Fig. 
14b). Decreased SNF5 binding was primarily associated with downregulation of target gene 
expression (Supplementary Table 6e), although the SWI/SNF complex is known to regulate 
expression in either direction24,25. An integrative GSEA analysis of the microarray and 
SNF5 ChIP-Seq data demonstrated a significant enrichment for genes that were repressed 
when SChLAP1 was overexpressed (q-value = 0.003, Fig. 4g). Overall, these data argue that 
SChLAP1 overexpression antagonizes SWI/SNF complex function by attenuating the 
genomic binding of this complex, thereby impairing its ability to regulate gene expression 
properly.
Here, we have discovered SChLAP1, a highly prognostic lncRNA that is abundantly 
expressed in ∼25% of prostate cancers and aided the discrimination of aggressive from 
indolent forms of this disease. Mechanistically, we find that SChLAP1 coordinates cancer 
cell invasion in vitro and metastatic spread in vivo. Moreover, we characterize an 
antagonistic SChLAP1-SWI/SNF axis in which SChLAP1 impairs SNF5-mediated gene 
expression regulation and genomic binding (Supplementary Fig. 14c). Thus, while other 
lncRNAs such as HOTAIR and HOTTIP are known to assist epigenetic complexes such as 
PRC2 and MLL by facilitating their genomic binding and enhancing their functions8,9,32, 
SChLAP1 is the first lncRNA, to our knowledge, that impairs a major epigenetic complex 
with well-documented tumor suppressor function23-25,33-35. Taken together, our discovery 
of SChLAP1 has broad implications for cancer biology and provides supporting evidence for 
the role of lncRNAs in the progression of aggressive cancers.
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Data Deposition
Sequences for SChLAP1 isoforms #1-7 have been deposited to GenBank as accession 
numbers JX117418 – JX117424. Microarray data have been deposited to GEO as accession 
number GSE40386.
Online Methods
Experimental studies
Cell lines—All cell lines were obtained from the American Type Culture Collection 
(Manassas, VA). Cell lines were maintained using standard media and conditions. 
Specifically, VCaP and Du145 cells were maintained in DMEM (Invitrogen) plus 10% fetal 
bovine serum (FBS) plus 1% penicillin-streptomycin. LNCaP and 22Rv1 were maintained 
in RPMI 1640 (Invitrogen) plus 10% FBS and 1% penicillin-streptomycin. RWPE cells 
were maintained in KSF media (Invitrogen) plus 10ng/mL EGF (Sigma) and bovine 
pituitary extract (BPE) and 1% penicillin-streptomycin. All cell lines were grown at 37°C in 
a 5% CO2 cell culture incubator. All cell lines were genotyped for identity at the University 
of Michigan Sequencing Core and tested routinely for Mycoplasma contamination.
SChLAP1 or control-expressing cell lines were generated by cloning SChLAP1 or control 
into the pLenti6 vector (Invitrogen) using pcr8 non-directional Gateway cloning (Invitrogen) 
as an initial cloning vector and shuttling to pLenti6 using LR clonase II (Invitrogen) 
according to the manufacturer's instructions. Stably-transfected RWPE and 22Rv1 cells 
were selected using blasticidin (Invitrogen) for one week. For LNCAP and 22Rv1 cells with 
stable knockdown of SChLAP1, cells were transfected with SChLAP1 or non-targeting 
shRNA lentiviral constructs for 48 hours. GFP+ cells were selected with 1ug/mL puromycin 
for 72 hours. All lentiviruses were generated by the University of Michigan Vector Core.
Tissue Samples—Prostate tissues were obtained from the radical prostatectomy series 
and Rapid Autopsy Program at the University of Michigan tissue core37. These programs are 
part of the University of Michigan Prostate Cancer Specialized Program Of Research 
Excellence (S.P.O.R.E.). All tissue samples were collected with informed consent under an 
Institutional Review Board (IRB) approved protocol at the University of Michigan. (SPORE 
in Prostate Cancer (Tissue/Serum/Urine) Bank Institutional Review Board # 1994-0481).
RNA isolation and cDNA synthesis—Total RNA was isolated using Trizol and an 
RNeasy Kit (Invitrogen) with DNase I digestion according to the manufacturer's 
instructions. RNA integrity was verified on an Agilent Bioanalyzer 2100 (Agilent 
Technologies, Palo Alto, CA). cDNA was synthesized from total RNA using Superscript III 
(Invitrogen) and random primers (Invitrogen).
Quantitative Real-time PCR—Quantitative Real-time PCR (qPCR) was performed using 
Power SYBR Green Mastermix (Applied Biosystems, Foster City, CA) on an Applied 
Biosystems 7900HT Real-Time PCR System. All oligonucleotide primers were obtained 
from Integrated DNA Technologies (Coralville, IA) and are listed in Supplementary Table 
7. The housekeeping genes, GAPDH, HMBS, and ACTB, were used as loading controls. Fold 
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changes were calculated relative to housekeeping genes and normalized to the median value 
of the benign samples.
Reverse-transcription PCR—Reverse-transcription PCR (RT-PCR) was performed for 
primer pairs using Platinum Taq High Fidelity polymerase (Invitrogen). PCR products were 
resolved on a 1.0% agarose gel. PCR products were either sequenced directly (if only a 
single product was observed) or appropriate gel products were extracted using a Gel 
Extraction kit (Qiagen) and cloned into pcr4-TOPO vectors (Invitrogen). PCR products were 
bidirectionally sequenced at the University of Michigan Sequencing Core using either gene-
specific primers or M13 forward and reverse primers for cloned PCR products. All 
oligonucleotide primers were obtained from Integrated DNA Technologies (Coralville, IA) 
and are listed in Supplementary Table 7.
RNA-ligase-mediated rapid amplification of cDNA ends (RACE)—5′ and 3′ RACE 
was performed using the GeneRacer RLM-RACE kit (Invitrogen) according to the 
manufacturer's instructions. RACE PCR products were obtained using Platinum Taq High 
Fidelity polymerase (Invitrogen), the supplied GeneRacer primers, and appropriate gene-
specific primers indicated in Supplementary Table 7. RACE-PCR products were separated 
on a 1.5% agarose gels. Gel products were extracted with a Gel Extraction kit (Qiagen), 
cloned into pcr4-TOPO vectors (Invitrogen), and sequenced bidirectionally using M13 
forward and reverse primers at the University of Michigan Sequencing Core. At least three 
colonies were sequenced for every gel product that was purified.
siRNA knockdown studies—Cells were plated in 100mM plates at a desired 
concentration and transfected with 20uM experimental siRNA oligos or non-targeting 
controls twice, at 8 hours and 24 hours post-plating. Knockdowns were performed with 
Oligofectamine in OptiMEM media. Knockdown efficiency was determined by qPCR. 
siRNA sequences (in sense format) for knockdowns were as follows:
SChLAP1 siRNA 1: CCAAUGAUGAGGAGCGGGA
SChLAP1 siRNA 2: CUGGAGAUGGUGAACCCAA
SNF5 siRNA 5: GUGACGAUCUGGAUUUGAA
SNF5 siRNA 7: GAUGACGCCUGAGAUGUUU
72 hours post-transfection, cells were trypsinized, counted with a Coulter counter, and 
diluted to 1 million cells/mL.
Overexpression studies—SChLAP1 full length transcript was amplified from LNCaP 
cells and cloned into the pLenti6 vector (Invitrogen) along with LacZ controls. Insert 
sequences were confirmed by Sanger sequencing at the University of Michigan Sequencing 
Core. Lentiviruses were generated at the University of Michigan Vector Core. The benign 
immortalized prostate cell line RWPE was infected with lentiviruses expressing SChLAP1 or 
LacZ and stable pools and clones were generated by selection with blasticidin (Invitrogen). 
Similarly, the immortalized cancer cell line 22Rv1 was infected with lentiviruses expressing 
SChLAP1 or LacZ and stable pools were generated by selection with blasticidin (Invitrogen).
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Cell proliferation assays—72 hours post-transfection with siRNA, cells were 
trypsinized, counted with a Coulter counter, and diluted to 1 million cells/mL. For 
proliferation assays, 10,000 cells were plated in 24-well plates and grown in regular media. 
48 and 96 hours post-plating, cells were harvested by trypsinizing and counted using a 
Coulter counter. All assays were performed in quadruplicate.
Basement Membrane Matrix Invasion Assays—For invasion assays, cells were 
treated with the indicated siRNAs and 72 hours post-transfection, cells were trypsinized, 
counted with a Coulter counter, and diluted to 1 million cells/mL. Cells were seeded onto 
the basement membrane matrix (EC matrix, Chemicon, Temecula, CA) present in the insert 
of a 24 well culture plate. Fetal bovine serum was added to the lower chamber as a chemo-
attractant. After 48 hours, the non-invading cells and EC matrix were gently removed with a 
cotton swab. Invasive cells located on the lower side of the chamber were stained with 
crystal violet, air-dried and photographed. For colorimetric assays, the inserts were treated 
with 150 μl of 10% acetic acid and the absorbance measured at 560nm using a 
spectrophotometer (GE Healthcare).
shRNA knockdown—The prostate cancer cell lines LNCaP and 22Rv1 were seeded at 
50-60% confluency and allowed to attach over night. Cells were transfected with SChLAP1 
or non-targeting shRNA lentiviral constructs as described previously for 48 hours. GFP+ 
cells were drug-selected using 1 ug/mL puromycin for 72 hours. 48 hours post-selection 
cells were harvested for protein and RNA using RIPA buffer or trizol, respectively. RNA 
was processed as described above.
Gene expression profiling—Expression profiling was performed using the Agilent 
Whole Human Genome Oligo Microarray (Santa Clara, CA), according to previously 
published protocols38. All samples were run in technical triplicates comparing knockdown 
samples treated with SChLAP1 siRNA compared to treatments with non-targeting control 
siRNA. Expression data was analyzed using the SAM method as described previously20.
Murine intracardiac and subcutaneous in vivo models—All experimental 
procedures were approved by the University of Michigan Committee for the Use and Care 
of Animals (UCUCA). Intracardiac injection model: 5 × 105 cells from one of three 
experimental cell lines (22Rv1 shNT, 22Rv1 shSChLAP1 #1, shSChLAP1 #2, all with 
luciferase constructs incorporated) were introduced to CB-17 severe combine 
immunodefiecient mice (CB-17 SCID) at 6 weeks of age. Female mice were used to 
minimize endogenous androgen production that may stimulate xenografted prostate cells. 15 
mice were used per cell line in order to ensure adequate statistical power to distinguish 
phenotypes between groups. Mice used in these studies were randomized by double-blind 
injection of cell line samples into mice and were monitored for tumor growth by researchers 
blinded to the study design. Beginning one week post injection, bioluminescent imaging of 
mice was performed weekly using a CCD IVIS system with a 50-mm lens (Xenogen Corp.) 
and the results were analyzed using LivingImage software (Xenogen). When the mice 
reached determined endpoint, whole body region of interest (ROI) of 1 × 1010 photons, or 
became fatally ill, the animal was euthanized and the lung and liver resected. Half of the 
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resected specimen was put in an immunohistochemistry cassette and placed in 10% buffered 
formalin phosphate (Fisher Scientific) for 24 hours, and then transferred to 70% ethanol 
until further analysis. The other half of each specimen was snap frozen in liquid nitrogen 
and stored in -80°C. A specimen was disregarded if the tumor was localized to the heart 
only. After accounting for these considerations, there were 9 mice analyzed for 22Rv1 shNT 
cells, 14 mice each analyzed for 22Rv1 shSChLAP1 #1 and #2 cells. Subcutaneous injection 
model: 1 × 106 cells from one of the three previously described experimental cell lines were 
introduced to mice (CB-17 SCID), ages 5-7 weeks, with a Matrigel scaffold (BD Matrigel 
Matrix, BD Biosciences) in the posterior dorsal flank region (n = 10 per cell line). Tumors 
were measured weekly using a digital caliper, and endpoint was determined as a tumor 
volume of 1000 mm3. When endpoint was reached, or the animal became fatally ill, the 
mouse was euthanized and the primary tumor resected. The resected specimen was divided 
in half: one half in 10% buffer formalin and the other half snap frozen. For histological 
analyses, FFPE-fixed mouse livers and lungs were sectioned on a microtome into 5uM 
sections onto glass slides. Slides were stained with hematoxalyn and eosin using standard 
methods and analyzed by a board-certified pathologist (LPK).
Immunoblot Analysis—Cells were lysed in RIPA lysis buffer (Sigma, St. Louis, MO) 
supplemented with HALT protease inhibitor (Fisher). Western blotting analysis was 
performed with standard protocols using Polyvinylidene Difluoride membrane (GE 
Healthcare, Piscataway, NJ) and the signals visualized by enhanced chemiluminescence 
system as described by the manufacturer (GE Healthcare).
Protein lysates were boiled in sample buffer, and 10 ug protein was loaded onto a SDS-
PAGE gel and run for separation of proteins. Proteins were transferred onto Polyvinylidene 
Difluoride membrane (GE Healthcare) and blocked for 90 minutes in blocking buffer (5% 
milk, 0.1% Tween, Tri-buffered saline (TBS-T)). Membranes were incubated overnight at 
4C with primary antibody. Following 3 washes with TBS-T, and one wash with TBS, the 
blot was incubated with horseradish peroxidase-conjugated secondary antibody and the 
signals visualized by enhanced chemiluminescence system as described by the manufacturer 
(GE Healthcare).
Primary antibodies used were:
SNF5 (1:1000, Millipore, ABD22, rabbit)
SNF5 (1:1000, Abcam, ab58209, mouse)
ACTB (1:5000, Sigma, rabbit)
AR (1:1000. Millipore, 06-680, rabbit)
RNA immunoprecipitation
RIP assays were performed using a Millipore EZ-Magna RIP RNA-Binding Protein 
Immunoprecipitation kit (Millipore, #17-701) according to the manufacturer's instructions. 
RIP-PCR was performed as qPCR, as described above, using total RNA as input controls. 
1:150th of RIP RNA product was used per PCR reaction. Antibodies used for RIP were 
Rabbit polyclonal IgG (Millipore, PP64), SNRNP70 (Millipore, CS203216), SNF5 
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(Millipore, ABD22), SNF5 (Abcam, ab58209), and AR (Millipore, 06-680, rabbit), using 5 
– 7 ug of antibody per RIP reaction. All RIP assays were performed in biological duplicate. 
For UV-crosslinked RIP experiments, cells were subjected to 400J of 254nM UV light twice 
and then harvested for RIP experiments as above.
Chromatin immunoprecipitation—ChIP assays were performed as described 
previously11,12, using antibodies for SNF5 (Millipore ABD22) and Rabbit IgG (Millipore 
PP64B). Briefly, approximately 10^6 cells were crosslinked per antibody for 10-15 minutes 
with 1% formaldehyde and the crosslinking was inactivated by 0.125M glycine for 5 
minutes at room temperature. Cells were rinsed with cold PBS three times and cell pellets 
were resuspended in lysis buffer plus protease inhibitors. Chromatin was sonicated to an 
average length of 500bp, centrifuged to remove debris, and supernatants containing 
chromatin fragments were incubated with protein A/G beads to reduce non-specific binding. 
Then, beads were removed and supernatants were incubated with 6ug of antibody overnight 
at 4C. Beads were added and incubated with protein-chromatin-antibody complexes for 2 
hours at 4C, washed twice with 1× dialysis buffer and four times with IP wash buffer, and 
eluted in 150 ul IP elution buffer. 1:10th of the ChIP reaction was taken for protein 
evaluation for validation of ChIP pull-down. Reverse crosslinking was performed by 
inclubating the eluted product with 0.3 M NaCl at 65C overnight. ChIP product was cleaned 
up with the USB PrepEase kit (USB). ChIP experiments were validated for specificity by 
Western blotting.
ChIP-Seq experiments—Paired-end ChIP-Seq libraries were generated following the 
Illimuna ChIP-Seq protocol with minor modifications. The ChIP DNA was subjected to end-
repair and A base addition before ligating with Illumina adaptors. Samples were purified 
using Ampure beads (Beckman Coulter Inc., Brea CA) and PCR-enriched with a 
combination of specific index primers and PE2.0 primer under the following conditions: 
98C (30 sec), 65C (30 sec), and 72C (40 sec with a 4 sec increment per cycle). After 14 
cycles of amplification a final extension at 72C for 5 minutes was carried out. The barcoded 
libraries were size-selected using a 3% NuSieve Agarose gele (Lonza, Allendale, NJ) and 
subjected to an additional PCR enrichment step. The libraries were analyzed and quantitated 
using Bio-Analyzer (Agilent Technologies, Santa Clara, CA) before subjecting it to paired-
end sequencing using the Illumina Hi-Seq platform.
CAM assays—CAM assays were performed as previously described39. Briefly, fertilized 
eggs were incubated in a rotary humidified incubator at 38°C for 10 days. CAM was 
released by applying mild amount of low pressure to the hole over the air sac and cutting a 1 
cm2 window encompassing a second hole near the allantoic vein. Approximately 2 million 
cells in 50μl of media were implanted in each egg, windows were sealed and the eggs were 
returned to a stationary incubator.
For local invasion and intravasation experiments, the upper and lower CAM were isolated 
after 72hr. The upper CAM were processed and stained for chicken collagen IV 
(immunofluorescence) or human cytokeratin (immunohistochemistry) as previously 
described39.
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For metastasis assay, the embryonic livers were harvested on day 18 of embryonic growth 
and analyzed for the presence of tumor cells by quantitative human Alu-specific PCR. 
Genomic DNA from lower CAM and livers were prepared using Puregene DNA purification 
system (Qiagen) and quantification of human-Alu was performed as described39. 
Fluorogenic TaqMan qPCR probes were generated as described above and used to 
determine DNA copy number.
For xenograft growth assay with RWPE cells, the embryos were sacrificed on day 18 and 
the extra-embryonic xenograft were excised and weighed.
In situ hybridization—ISH assays were performed as a commercial service from 
Advanced Cell Diagnostics, Inc. Briefly, cells in the clinical specimens are fixed and 
permeablized using xylenes, ethanol, and protease to allow for probe access. Slides are 
boiled in pretreatment buffer for 15 min and rinsed in water. Next, two independent target 
probes are hybridized to the SChLAP1 RNA at 40C for 2 hours, with this pair of probes 
creating a binding site of a preamplifier. After this, the preamplifier is hybridized to the 
target probes at 30C and amplified with 6 cycles of hybridization followed by 2 washes. 
Cells are counter-stained to visualize signal. Finally, slides are H&E stained, dehydrated 
with 100% ethanol and xylene, and mounted in a xylene-based mounting media.
In vitro translation—Full length SChLAP1, PCAT-1, or GUS positive control were cloned 
into the PCR2.1 entry vector (Invitrogen). Insert sequences were confirmed by Sanger 
sequencing at the University of Michigan Sequencing Core. In vitro translation assays were 
performed with the TnT Quick Coupled Transcription/Translation System (Promega) with 
1mM methionine and Transcend Biotin-Lysyl-tRNA (Promega) according to the 
manufacturer's instructions.
ChIRP Assay—ChIRP assays were performed as previously described40. Briefly, 
antisense DNA probes targeting the SChLAP1 full-length sequence were designed using the 
online designer at http://www.singlemoleculefish.com. Fifteen probes spanning the entire 
transcript and unique to the SChLAP1 sequence were chosen. Additionally, ten probes were 
designed against TERC RNA as a positive control and twenty-four probes were designed 
against LacZ RNA as a negative control. All probes were synthesized with 3′ biotinylation 
(IDT). Sequences of all probes are listed in Supplementary Table 8. RWPE cells 
overexpressing SChLAP1 isoform 1 were grown to 80% confluency in 100mm cell culture 
dishes. Two dishes were used for each probe set. Prior to harvesting, the cells were rinsed 
with 17times;PBS and crosslinked with 1% glutaraldehyde (Sigma) for 10 min at room 
temperature. Crosslinking was quenched with 0.125M glycine for 5 min at room 
temperature. The cells were rinsed twice with 1×PBS, collected and pelleted at 1500×g for 5 
min. Nuclei were isolated using the Pierce NE-PER Nuclear Protein Extraction Kit. The 
nuclear pellet was resuspended in 100mg/ml cell lysis buffer (50 mM Tris, pH 7.0, 10 mM 
EDTA, 1% SDS, and added before use: 1 mM dithithreitol (DTT), phenylmethylsulphonyl 
fluoride (PMSF), protease inhibitor and Superase-In (Invitrogen)). The lysate was placed on 
ice for 10 min and sonicated using a Bioruptor (Diagenode) at the highest setting with 30 sec 
on and 45 sec off cycles until lysates were completely solubilized. Cell lysates were diluted 
in twice the volume of hybridization buffer (500 mM NaCl, 1% SDS, 100 mM Tris, pH 7.0, 
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10 mM EDTA, 15% formamide, and added before use: DTT, PMSF, protease inhibitor, and 
Superase-In) and 100pmol/ml probes were added to the diluted lysate. Hybridization was 
carried out by end-over-end rotation at 37 °C for 4 hours. Magnetic streptavidin C1 beads 
were prepared by washing three times in cell lysis buffer and then added to each 
hybridization reaction at 100ul per 100pmol of probes. The reaction was incubated at 37°C 
for 30 min with end-over-end rotation. Bead–probe–RNA complexes were captured with 
magnetic racks (Millipore) and washed five times with 1mL wash buffer (2×SSC, 0.5% 
SDS, fresh PMSF added). After the last wash, 20% of the sample was used for RNA 
isolation and 80% of the sample was used for protein isolation. For RNA elution, beads were 
resuspended in 200μl of RNA proteinase K buffer (100 mM NaCl, 10 mM Tris, pH 7.0, 1 
mM EDTA, 0.5% SDS) and 1mg/ml proteinase K (Ambion). The sample was incubated at 
50°C for 45 min and then boiled for 10 min. RNA was isolated using 500ul of Trizol reagent 
using the miRNeasy kit (Qiagen) with on-column DNase digestion (Qiagen). RNA was 
eluted with 10ul H2O and then analyzed by qRT–PCR for the detection of enriched 
transcripts. For protein elution, beads were resuspended in 3× the original volume of DNase 
buffer (100 mM NaCl and 0.1% NP-40), and protein was eluted with a cocktail of 100 ug/ml 
RNase A (Sigma-Aldrich), 0.1 Units/microliter RNase H (Epicenter), and 100 U/ml DNase I 
(Invitrogen) at 37°C for 30 min. The eluted protein sample was supplemented with 
NuPAGE® LDS Sample Buffer (Novex) and NuPAGE® Sample Reducing Agent (Novex) 
to a final concentration of 1× each and then boiled for 10 min before SDS-PAGE Western 
blot analysis using a SNF5 antibody (Millipore).
RNA-Seq Library Preparation—Total RNA was extracted from healthy and cancer cell 
lines and patient tissues, and the quality of the RNA were assessed with the Agilent 
Bioanalyzer. Transcriptome libraries from the mRNA fractions were generated following the 
RNA-Seq protocol (Illumina). Each sample was sequenced in a single lane with the Illumina 
Genome Analyzer II (with a 40- to 80-nt read length) or with the Illumina HiSeq 2000 (with 
a 100-nt read length) according to published protocols11,41. For strand-specific library 
construction, we employed the dUTP method of second-strand marking as described 
previously42.
Statistical analyses for experimental studies—All data are presented as means ± 
S.E.M. All experimental assays were performed in duplicate or triplicate. Statistical analyses 
shown in figures represent Fisher's exact tests or two-tailed t-tests, as indicated. For details 
regarding the statistical methods employed during microarray, RNA-Seq and ChIP-Seq data 
analysis, see Bioinformatic analyses.
Bioinformatics Analysis
Nomination of SChLAP1 as an outlier using RNA-Seq data—We nominated 
SChLAP1 as a prostate cancer outlier using the methodology detailed in Prensner JR et al., 
Nature Biotechnology 2011. Briefly, a modified COPA analysis was performed on the 81 
tissue samples in the cohort. RPKM expression values were used and shifted by 1.0 in order 
to avoid division by zero. The COPA analysis had the following steps: 1) gene expression 
values were median centered, using the median expression value for the gene across the all 
samples in the cohort. This sets the gene's median to zero. 2) The median absolute deviation 
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(MAD) was calculated for each gene, and then each gene expression value was scaled by its 
MAD. 3) The 80, 85, 90, 98 percentiles of the transformed expression values were 
calculated for each gene and the average of those four values was taken. Then, genes were 
rank ordered according to this “average percentile”, which generated a list of outliers genes 
arranged by importance. 4) Finally, genes showing an outlier profile in the benign samples 
were discarded.
LNCaP ChIP-Seq data—Sequencing data from GSE14097 were downloaded from GEO. 
Reads from the LNCAP H3K4me3 and H3K36me3 ChIP-Seq samples were mapped to 
human genome version hg19 using BWA 0.5.943. Peak calling was performed using 
MACS44 according to the published protocols45. Data was visualized using the UCSC 
Genome Browser46.
RWPE ChIP-Seq data—Sequencing data from RWPE SNF5 ChIP-Seq samples were 
mapped to human genome version hg19 using BWA 0.5.943. Although we performed 
paired-end sequencing, the ChIP-Seq reads were processed as single-end to adhere to our 
preexisting analysis protocol. Basic read alignment statistics are listed in Supplementary 
Table 6A. Peak calling was performed respect to an IgG control using the MACS 
algorithm44. We bypassed the model-building step of MACS (using the ‘--nomodel’ flag) 
and specified a shift size equal to half the library fragment size determined by the Agilent 
Bioanalyzer (using the ‘--shiftsize’ option). For each sample we ran the CEAS program and 
generated genome-wide reports47. We retained peaks with an false discovery rate (FDR) less 
than 5% (peak calling statistics across multiple FDR thresholds are shown in Supplementary 
Table 6B). We then aggregated SNF5 peaks from the RWPE-LacZ, RWPE-SChLAP1 
Isoform #1, and RWPE-SChLAP1 Isoform #2 samples using the “union” of the genomic 
peak intervals. We intersected peaks with RefSeq protein-coding genes and found that 1,299 
peaks occurred within one kilobase of transcription start sites (TSSs). We counted the 
number of reads overlapping each of these promoter peaks across each sample using a 
custom python script and used the DESeq R package version 1.6.148 to compute the 
normalized fold change between RWPE-LacZ and RWPE-SChLAP1 (both isoforms). We 
observed that 389 of the 1,299 promoter peaks had at least a 2-fold average decrease in 
SNF5 binding. This set of 389 genes was subsequently used as a gene set for Gene Set 
Enrichment Analysis (GSEA) (Supplementary Table 6C).
Microarray Gene Expression Analysis
Microarray experiments—We performed two-color microarray gene expression 
profiling of 22Rv1 and LNCaP cells treated with two independent siRNAs targeting 
SChLAP1 as well as control non-targeting siRNAs. These profiling experiments were run in 
technical triplicate for a total of 12 arrays (6 from 22Rv1 and 6 from LNCaP). Additionally, 
we profiled 22Rv1 and LNCaP cells treated with independent siRNAs targeting SWI/SNF 
protein SNF5 (SMARCB1) as well as control non-targeting siRNAs. These profiling 
experiments were run as biological duplicates for a total of 4 arrays (2 cell lines × 2 
independent siRNAs × 1 protein). Finally, we profiled of RWPE cells expressing two 
different SChLAP1 isoforms as well as the control LacZ gene. These profiling experiments 
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were run in technical duplicate for a total of 4 arrays (2 from RWPE-SChLAP1 isoform #1 
and 2 from RWPE-SChLAP1 isoform #2).
Processing to determine ranked gene expression lists—All of the microarray data 
were represented as base-2 log fold-change between targeting versus control siRNAs. We 
used the CollapseDataset tool provided by the GSEA package to convert from Agilent Probe 
IDs to gene symbols. Genes measured by multiple probes were consolidated using the 
median of probes. We then ran one-class SAM analysis from the Multi-Experiment Viewer 
application and ranked all genes by the difference between observed versus expected 
statistics. These ranked gene lists was imported to GSEA version 2.07.
SChLAP1 siRNA knockdown microarrays—For the 22Rv1 and LNCaP SChLAP1 
knockdown experiments we ran the GseaPreRanked tool to discover enriched gene sets in 
the Molecular Signatures Database (MSigDB) version 3.022. Lists of positively and 
negatively enriched concepts were interpreted manually.
SNF5 siRNA knockdown microarrays—For each SNF5 protein knockdown we 
nominated genes that were altered by an average of at least 2-fold. These signatures of 
putative SNF5 target genes were then used to assess enrichment of SChLAP1-regulated 
genes using the GseaPreRanked tool. Additionally, we nominated genes that changed by an 
average 2-fold or greater across SNF5 knockdown experiments and quantified the 
enrichment for SChLAP1 target genes using GSEA.
RWPE SChLAP1 expression microarrays—The RWPE-SChLAP1 versus RWPE-
LacZ expression profiles were ranked using SAM analysis as described above. A total of 
1,245 genes were significantly over- or under-expressed and are shown in Supplementary 
Table 6D. A q-value of 0.0 in this SAM analysis signifies that no permutation generated a 
more significant difference between observed and expected gene expression ratios. The 
ranked gene expression list was used as input to the GseaPreRanked tool and compared 
against SNF5 ChIP-Seq promoter peaks that decreased by >2-fold in RWPE-SChLAP1 cells. 
Of the 389 genes in the ChIP-Seq gene set, 250 were profiled by the Agilent HumanGenome 
microarray chip and present in the GSEA gene symbol database. An expression profile 
across these 250 genes is in Supplementary Table 6E.
RNA-Seq data—We assembled an RNA-Seq cohort from prostate cancer tissues 
sequenced at multiple institutions. We included data 12 primary tumors and 5 benign tissues 
published in GEO as GSE2226049, 16 primary tumors and 3 benign tissues released in 
dbGAP as study phs000310.v1.p150, and 17 benign, 57 primary, 14 metastatic tumors 
sequenced by our own institution and released as dbGAP study phs000443.v1.p1. 
Supplementary Table 1A shows sample information, and Supplementary Table 1B shows 
sequencing library information.
RNA-Seq alignment and gene expression quantification—Sequencing data were 
aligned using Tophat version 1.3.151 against the Ensembl GRCh37 human genome build. 
Known introns (Ensembl release 63) were provided to Tophat. Gene expression across the 
Ensembl version 63 genes and the SChLAP1 transcript was quantified by HT-Seq version 
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0.5.3p3 using the script htseq-count (www-huber.embl.de/users/anders/HTSeq/). Reads were 
counted without respect to strand to avoid bias between unstranded and strand-specific 
library preparation methods. This bias results from the inability to resolve reads in regions 
where two genes on opposite strands overlap in the genome.
RNA-Seq differential expression analysis—Differential expression analysis was 
performed using R package DESeq version 1.6.148. Read counts were normalized using the 
estimateSizeFactors function and variance was modeled by the estimateDispersions 
function. Differentially expression statistics were computed by the nbinomTest function. We 
called differentially expressed genes by imposing adjusted p-value cutoffs for cancer versus 
benign (padj < 0.05), metastasis versus primary (padj < 0.05), and gleason 8+ versus 6 (padj 
< 0.10). Heatmap visualizations for these analyses are presented as Supplementary Fig. 5.
RNA-Seq correlation analysis—Read count data were normalized using functions from 
the R package DESeq version 1.6.1. Adjustments for library size were made using the 
estimateSizeFactors function and variance was modeled using the estimateDispersions 
function using the parameters “method=blind” and “sharingMode=fit-only”. Next, the raw 
read count data was converted to pseudo-counts using the getVarianceStabilizedData 
function. Gene expression levels were then mean-centered and standardized using the scale 
function in R. Pearson correlation coefficients were computed between each gene of interest 
and all other genes. Statistical significance of Pearson correlations was determined by 
comparison to correlation coefficients achieved by 1,000 random permutations of the 
expression data. We controlled for multiple hypothesis testing using the qvalue package in 
R. The 253-gene SChLAP1 correlation signature was determined by imposing a cutoff of q 
< 0.05.
Oncomine Concepts Analysis of SChLAP1 Signature—We separated the 253 
genes with expression levels significantly correlated to SChLAP1 into positively and 
negatively correlated gene lists. We imported these gene lists into Oncomine as custom 
concepts. We then nominated significantly associated Prostate Cancer concepts with Odds 
Ratio > 3.0 and p-value < 10-6. We exported these results as nodes and edges of a concept 
association network, and visualized the network using Cytoscape version 2.8.2. The node 
positions were computed using the Force Directed Layout algorithm in Cytoscape using the 
odds ratio as the edge weight. Node positions were subtly altered manually to enable better 
visualization of node labels.
Association of Correlation Signatures with Oncomine Concepts—We applied 
our RNA-Seq correlation analysis procedure on the genes SChLAP1, EZH2, PCA3, AMACR, 
ACTB. For each gene we created signatures from the top 5 percent of positively and 
negatively correlated genes (Supplementary Table 3). We performed a large meta-analysis 
of these correlation signatures across Oncomine datasets corresponding to disease outcome 
(Glinsky Prostate, Setlur Prostate), metastatic disease (Holzbeierlein Prostate, Lapointe 
Prostate, LaTulippe Prostate, Taylor Prostate 3, Vanaja Prostate, Varambally Prostate, and 
Yu Prostate), advanced gleason score (Bittner Prostate, Glinsky Prostate, Lapointe Prostate, 
LaTulippe Prostate, Setlur Prostate, Taylor Prostate 3, and Yu Prostate), and localized 
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cancer (Arredouani Prostate, Holzbeierlein Prostate, Lapointe Prostate, LaTulippe Prostate, 
Taylor Prostate 3, Varambally Prostate, and Yu Prostate). We also incorporated our own 
concept signatures for metastasis, advanced Gleason score, and localized cancer determined 
from our RNA-Seq data. For each concept we downloaded the gene signatures 
corresponding to the Top 5 Percent of genes up- and down-regulated. Pairwise signature 
comparisons were performed using a one-sided Fisher's Exact Test. We controlled for 
multiple hypothesis testing using the qvalue package in R. We considered concept pairs with 
q < 0.01 and odds ratio > 2.0 as significant. In cases where a gene signature associates with 
both the over- and under-expression gene sets from a single concept, only the most 
significant result (as determined by odds ratio) is shown.
Analysis of SChLAP1-SNF5 expression signatures—The siSCHLAP1 and siSNF5 
gene signatures were generated from Agilent gene expression microarray datasets. For each 
cell line we obtained a single vector of per-gene fold changes by averaging technical 
replicates and then taking the median across biological replicates. We merged the individual 
cell line results using the median of the changes in 22Rv1 and LNCaP. Venn diagram plots 
were produced using the BioVenn website (http://www.cmbi.ru.nl/cdd/biovenn/)52. We then 
compared the top 10% up-regulated and down-regulated genes for siSChLAP1 and siSNF5 
to gene signatures downloaded from the Taylor Prostate 3 dataset in the Oncomine database. 
We performed signature comparison using one-sided Fisher's Exact Tests and controlled for 
multiple testing using the R package “qvalue”. Signature comparisons with q < 0.05 were 
considered significantly enriched. We plotted the odds ratios from significant comparison 
using the “heatmap.2” function in the “gplots” R package.
Kaplan-Meier Survival Analysis Based on SChLAP1 Gene Signature—We 
downloaded prostate cancer expression profiling data and clinical annotations from 
GSE8402 published by Setlur et. al.17. We intersected the 253-gene SChLAP1 signature 
with the genes in this dataset and 80 genes in common. We then assigned SChLAP1 
expression scores to each patient sample in the cohort using the un-weighted sum of 
standardized expression levels across the 80 genes. Given that we observed SChLAP1 
expression in approximately 20% of prostate cancer samples, we used the 80th percentile of 
SChLAP1 expression scores as the threshold for “high” versus “low” scores. We then 
performed 10-year survival analysis using the survival package in R and computed statistical 
significance using the log-rank test.
Additionally, we imported the 253-gene SChLAP1 signature into Oncomine in order to 
download the expression data for 167 of the 253 genes profiled by the Glinsky prostate 
dataset16. We assigned SChLAP1 expression scores in a similar fashion and designated the 
top 20% of patients as “high” for SChLAP1. We performed survival analysis using the time 
to biochemical PSA recurrence and computed statistical significance as above.
PhyloCSF Analysis—46-way multi-alignment FASTA files for SChLAP1, HOTAIR, 
GAPDH, and ACTB were obtained using the “Stitch Gene blocks” tool within the Galaxy 
bioinformatics framework (usegalaxy.org). We evaluated each gene for its likelihood to 
represent a protein-coding region using the PhyloCSF software (version released 
2012-10-28). Each gene was evaluated using the phylogeny from 29 mammals (available by 
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default within PhyloCSF) in any of the 3 reading frames. Scores are measured in decibans 
and reflect the likelihood that a predicted protein coding sequence is preferred over its non-
coding counterpart.
Mayo Clinic Cohort Analyses
Study Design—Patients were selected from a cohort of high-risk radical prostatectomy 
(RP) patients from the Mayo Clinic. The cohort was defined as 1010 high-risk men that 
underwent RP between 2000 -2006, of which 73 patients developed clinical progression 
(defined as patients with systemic disease as evidenced by positive bone or CT scan)53. 
High-risk of recurrence was defined as pre-operative PSA >20 ng/ml, pathological Gleason 
score 8-10, seminal vesicle invasion (SVI), or GPSM score >=1054. The sub-cohort 
incorporated all 73 CP progression patients and a 20% random sampling of the entire cohort 
(202 men including 19 with CP). The total case-cohort study was 256 patients, of which 
tissue specimens were available for 235 patients. The sub-cohort was previously used to 
validate a genomic classifier (GC) for predicting Clinical Progression53.
Tissue Preparation—Formalin-fixed paraffin embedded (FFPE) samples of human 
prostate adenocarcinoma prostatectomies were collected from patients with informed 
consent at the Mayo Clinic according to an institutional review board-approved protocol. 
Pathological review of H&E tissue sections was used to guide macrodissection of tumour 
from surrounding stromal tissue from three to four 10 μm sections. The index lesion was 
considered the dominant lesion by size.
RNA Extraction and Microarray Hybridization—For validation cohort, total RNA 
was extracted and purified using a modified protocol for the commercially available RNeasy 
FFPE nucleic acid extraction kit (Qiagen Inc., Valencia, CA). RNA concentrations were 
calculated using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, 
Rockland, DE). Purified total RNA was subjected to whole-transcriptome amplification 
using the WT-Ovation FFPE system according to the manufacturer's recommendation with 
minor modifications (NuGen, San Carlos, CA). For the validation only the Ovation® FFPE 
WTA System was used. Amplified products were fragmented and labelled using the 
Encore™ Biotin Module (NuGen, San Carlos, CA) and hybridized to Affymetrix Human 
Exon (HuEx) 1.0 ST GeneChips following manufacturer's recommendations (Affymetrix, 
Santa Clara, CA).
Microarray Expression Analysis—The normalization and summarization of the 
microarray samples was done with the frozen Robust Multiarray Average (fRMA) algorithm 
using custom frozen vectors. These custom vectors were created using the vector creation 
methods as described previously55. Quantile normalization and robust weighted average 
methods were used for normalization and summarization, respectively, as implemented in 
fRMA.
Statistical Analysis—Given the exon/intron structure of isoform 1 of SChLAP1, all probe 
selection regions (or PSRs) that fall within the genomic span of SChLAP1 were inspected 
for overlapping with any of the exons of this gene. One PSR, 2518129, was found fully 
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nested within the third exon of SChLAP1 and was used for further analysis as a 
representative PSR for this gene. The PAM (Partition Around Medoids) unsupervised 
clustering method was used on the expression values of all clinical samples to define two 
groups of high and low expression of SChLAP1.
Statistical analysis on the association of SChLAP1 with clinical outcomes was done using 
three endpoints (i) Biochemical Recurrence, defined as two consecutive increases of 
>=0.2ng/ml after RP, (ii) Clinical Progression, defined as a positive CT or bone scan and 
(iii) Prostate Cancer Specific Mortality (or PCSM).
For CP end point, all patients with CP were included in the survival analysis, whereas the 
controls in the sub-cohort were weighted in a 5-fold manner in order to be representative of 
patients from the original cohort. For PCSM end point, patients from the cases who did not 
die by PCa were omitted, and weighting was applied in a similar manner. For BCR, since 
the case-cohort was designed based on CP endpoint, resampling of BCR patients and sub-
cohort was done in order to have a representative of the selected BCR patients from the 
original cohort.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Discovery of SChLAP1 as a prostate cancer lncRNA
(a) Cancer outlier profile analysis (COPA) for intergenic lncRNAs. (b) A representation of 
the SChLAP1 gene and its annotations in current databases. An aggregated representation of 
current gene annotations for Ensembl, ENCODE, UCSC, Ref-Seq, and Vega shows no 
annotation for SChLAP1. ChIP-Seq data for H3K4me3 and H3K36me3 show enrichment at 
the SChLAP1 gene. Also, RNA-Seq data showing an outlier sample for SChLAP1 illustrates 
its expression. (c) qPCR for SChLAP1 on a panel of benign prostate (n=33), localized 
prostate cancer (n=82), and metastatic prostate cancer (n=33) samples. qPCR data is 
normalized to the average of (GAPDH + HMBS) and represented as standardized expression 
values. (d) Fractionation of prostate cell lysates demonstrates nuclear expression of 
SChLAP1. U1 is a positive control for nuclear gene expression. (e)In situ hybridization of 
SChLAP1 in human prostate cancer. SChLAP1 staining is shown for both localized and 
metastatic tissues.
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Figure 2. SChLAP1 expression characterizes aggressive prostate cancer
(a) Network representation of genes positively or negatively correlated with SChLAP1 in 
localized prostate cancers using Oncomine concepts analysis and visualized with the Force 
Directed Layout algorithm in the Cytoscape36 tool. Node sizes reflect the number of genes 
that comprise each molecular concept and node names are labeled according to the author of 
the primary study as detailed in Supplementary Table 3b. The nodes are colored according 
to the concept categories indicated in the figure legend. Edges are drawn between nodes 
with statistically significant enrichment (p-value < 1e-6, odds ratio > 3.0) and darker edge 
shading implies higher odds ratio. (b) Heatmap representation of comparisons between co-
expression gene signatures and molecular concepts. Comparisons to positively (top portion) 
and negatively correlated (bottom portion) gene signatures are shown separately. 
Comparisons that do not reach statistical significance (q > 0.01 or odds ratio < 2) are shown 
in grey. Associations with over-expression concepts are colored red, and under-expression 
concepts blue. (c-e) Kaplan-Meier analyses of prostate cancer outcomes in the Mayo Clinic 
cohort. SChLAP1 expression was measured using Affymetrix exon arrays and patients were 
stratified according to their SChLAP1 expression. Patient outcomes were analyzed for 
biochemical recurrence (c), clinical progression to systemic disease (d), and prostate cancer-
specific mortality (e). The shaded regions represent the 95% confidence interval.
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Figure 3. SChLAP1 coordinates cancer cell invasion in vitro and metastatic seeding in vivo
(a) siRNA knockdown of SChLAP1 in vitro in three prostate cell lines (LNCaP, 22Rv1, 
Du145) impairs cellular invasion through Matrigel in a Boyden chamber assay. EZH2 
siRNA serves as a positive control. (b) Overexpression of SChLAP1 in RWPE cells results 
in increased cellular invasion through Matrigel in Boyden chamber assays. (c) Intracardiac 
injection of 22Rv1 cells with stable SChLAP1 knockdown in severe combined 
immunodeficient (SCID) mice. Example luciferase bioluminescence images from 22Rv1 
shNT, shSChLAP1 #1, and shSChLAP1 #2 mice five weeks following intracardiac injection. 
Mouse IDs are given above each image. (d) The relative intensity of whole-mouse luciferase 
signal is plotted for 22Rv1 shNT (n=9), shSChLAP1 #1 (n=14) and shSChLAP1 #2 (n=14) 
intracardiac injection experiments. (e) The number of gross metastatic sites observed by 
luciferase signal in 22Rv1 shSChLAP1 cells or shNT controls. Independent foci of luciferase 
signal were averaged for shNT (n=9), shSChLAP1 #1 (n=14) and shSChLAP1 #2 (n=14) 
mice. (f) Invasion of 22Rv1-shNT and 22Rv1 shSChLAP1 cells in the chick chorioallantoic 
membrane (CAM) assay. 22Rv1 cells are labeled with GFP. The image is counterstained 
with chicken collagen IV for vasculature (RFP) and DAPI for nuclei. (g-i) Using the CAM 
assay, 22Rv1 shSChLAP1 cells demonstrate decreased intravasation (g), metastatic spread to 
the liver and lungs (h), and reduced tumor weight (i). (j) Quantification of intravasation of 
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RWPE-LacZ and RWPE-SChLAP1 cells in the CAM assay. All data in this figure are 
represented as mean +/- S.E.M. Statistical significance was determined by a two-tailed 
Student's t-test. An asterisk (*) indicates a p-value < 0.05.
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Figure 4. SChLAP1 antagonizes SNF5 function and attenuates SNF5 genome-wide localization
(a) Heatmap results for SChLAP1 or SNF5 knockdown in LNCaP and 22Rv1 cells. (b) RNA 
immunoprecipitation (RIP) of SNF5 or AR in SNF5 in 22Rv1 and LNCaP cells. Inset 
Western blots demonstrate pulldown efficiency. (c) RIP analysis of SNF5 in RWPE cells 
overexpressing LacZ, SChLAP1 isoform #1, or SChLAP1 isoform #2. Inset Western blots 
demonstrate pulldown efficiency. (d) Pulldown of SChLAP1 RNA using Chromatin 
Isolation by RNA Purification (ChIRP) recovers SNF5 protein in RWPE-SChLAP1 isoform 
1 cells. LacZ and TERC serve as controls. (e) A global representation of SNF5 genomic 
binding over ±2kb window surrounding each SNF5 ChIP-Seq peak in RWPE-LacZ, RWPE-
SChLAP1 isoform 1, and RWPE-SChLAP1 isoform 2 cells. (f) A heatmap representation of 
SNF genomic binding at target sites in RWPE-LacZ, RWPE-SChLAP1 isoform 1, and 
RWPE-SChLAP1 isoform 2 cells. A ±1kb interval surrounding the called SNF5 peak is 
shown. (g) Gene set enrichment analysis results showing significant enrichment of ChIP-Seq 
promoter peaks with >2-fold loss of SNF5 binding for underexpressed genes in RWPE-
SChLAP1 cells.
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